Naloxone Hydrochloride Study for Relief of Pruritus/Itch

Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL

Purpose
This multi-center, double-blind, vehicle-controlled, randomized crossover design study will evaluate the safety and efficacy of topically applied naloxone lotion, 0.5%, for the treatment of pruritus in patients with the mycosis fungoides (MF) or Sézary syndrome (SS) Forms of Cutaneous T-cell Lymphoma (CTCL). This study will also determine if there is systemic absorption of the drug in a subset of subjects and if so, describe the range and mean plasma levels reached after two weeks of three time daily (TID) dosing.

Website: https://clinicaltrials.gov/ct2/show/NCT02811783?term=elorac&rank=2

Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. 

Please refer to this study by its ClinicalTrials.gov identifier: NCT02811783

Contacts
Contact: Scott B Phillips, MD    8473628200    scott@eloracpharma.com    
Contact: Heidi Fezatte, BS    8473628200    hfezatte@eloracpharma.com

Sponsors and Collaborators
Elorac, Inc

Locations

United States, Missouri
Washington University School of Medicine St. Louis    Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Mary Tabacchi       mtabacchi@wustl.edu   
Principal Investigator: Amy Musiek, MD